Literature DB >> 15613327

Analysis of translational initiation in coxsackievirus B3 suggests an alternative explanation for the high frequency of R+4 in the eukaryotic consensus motif.

Stephanie Harkins1, Christopher T Cornell, J Lindsay Whitton.   

Abstract

Translational initiation of most eukaryotic mRNAs occurs when a preinitiation complex binds to the 5' cap, scans the mRNA, and selects a particular AUG codon as the initiation site. Selection of the correct initiation codon relies, in part, on its flanking residues; in mammalian cells, the core of the "Kozak" consensus is R-3CCAUGG+4 (R=purine; the A residue is designated position +1). The R-3 is considered the most important flanking residue, followed by G+4. Picornaviral mRNAs differ from most cellular mRNAs in several ways; they are uncapped, and they contain an internal ribosome entry site that allows the ribosome to bind near the initiation codon. The initiation codon of coxsackievirus B3 (CVB3) is flanked by both R-3 and G+4 (AAAATGG). Here, we report the construction of full-length CVB3 genomes that vary at these two positions, and we evaluate the effects of these variant sequences in vitro, in tissue culture cells, and in vivo. A virus with an A-->C transversion at position -3 replicates as well as wild-type CVB3, both in tissue culture and in vivo. This virus is highly pathogenic, and its sequence is stable throughout the course of an in vivo infection. Furthermore, the in vitro translation products from this RNA are very similar to the wild type. Thus, R-3-thought to be the most functionally important component of the Kozak consensus-appears to be dispensable in CVB3. In contrast, a G-to-C transversion at G+4 is lethal; RNAs carrying this mutation fail to generate infectious virus either in tissue culture or in vivo. However, in vitro analysis indicates that G+4 has only a marginal effect on translational initiation, especially if R-3 is present; instead, the G+4 is required mainly because the second triplet of the polyprotein open reading frame must encode glycine, without which infectious virus production cannot proceed. In summary, our data indicate that CVB3 remains viable, even in vivo, in the absence of R-3, and we propose that the most important factor contributing to the high frequency of G+4-not only in CVB but also in other eukaryotic mRNAs, and thus in the consensus motif itself-may be the constraint upon the second amino acid rather than the requirements for translational initiation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613327      PMCID: PMC538586          DOI: 10.1128/JVI.79.2.987-996.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  A reassessment of the translation initiation codon in vertebrates.

Authors:  S Peri; A Pandey
Journal:  Trends Genet       Date:  2001-12       Impact factor: 11.639

2.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 4.  The group B coxsackieviruses and myocarditis.

Authors:  K S Kim; G Hufnagel; N M Chapman; S Tracy
Journal:  Rev Med Virol       Date:  2001 Nov-Dec       Impact factor: 6.989

5.  Correlation between sequence conservation of the 5' untranslated region and codon usage bias in Mus musculus genes.

Authors:  H Sakai; T Washio; R Saito; A Shinagawa; M Itoh; K Shibata; P Carninci; H Konno; J Kawai; Y Hayashizaki; M Tomita
Journal:  Gene       Date:  2001-10-03       Impact factor: 3.688

6.  Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.

Authors:  A Henke; R Zell; G Ehrlich; A Stelzner
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Immunogenicity of a foreign peptide expressed within a capsid protein of an attenuated coxsackievirus.

Authors:  S S Halim; S E Ostrowski; W T Lee; A I Ramsingh
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

8.  Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology.

Authors:  I Mena; C Fischer; J R Gebhard; C M Perry; S Harkins; J L Whitton
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

Review 9.  Pushing the limits of the scanning mechanism for initiation of translation.

Authors:  Marilyn Kozak
Journal:  Gene       Date:  2002-10-16       Impact factor: 3.688

10.  MYRbase: analysis of genome-wide glycine myristoylation enlarges the functional spectrum of eukaryotic myristoylated proteins.

Authors:  Sebastian Maurer-Stroh; Masaki Gouda; Maria Novatchkova; Alexander Schleiffer; Georg Schneider; Fernanda L Sirota; Michael Wildpaner; Nobuhiro Hayashi; Frank Eisenhaber
Journal:  Genome Biol       Date:  2004-02-13       Impact factor: 13.583

View more
  11 in total

1.  Human astrocytic cells support persistent coxsackievirus B3 infection.

Authors:  Xiaowei Zhang; Zhenhua Zheng; Bo Shu; Xijuan Liu; Zhenfeng Zhang; Yan Liu; Bingke Bai; Qinxue Hu; Panyong Mao; Hanzhong Wang
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  Inhibition of protein trafficking by coxsackievirus b3: multiple viral proteins target a single organelle.

Authors:  Christopher T Cornell; William B Kiosses; Stephanie Harkins; J Lindsay Whitton
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Stress Granule Formation is One of the Early Antiviral Mechanisms for Host Cells Against Coxsackievirus B Infection.

Authors:  Xia Zhai; Shuo Wu; Lexun Lin; Tianying Wang; Xiaoyan Zhong; Yang Chen; Weizhen Xu; Lei Tong; Yan Wang; Wenran Zhao; Zhaohua Zhong
Journal:  Virol Sin       Date:  2018-06-29       Impact factor: 4.327

4.  Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo.

Authors:  Christopher C Kemball; Mehrdad Alirezaei; Claudia T Flynn; Malcolm R Wood; Stephanie Harkins; William B Kiosses; J Lindsay Whitton
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

5.  Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice.

Authors:  Feng He; Hailan Yao; Jianmin Wang; Zonghui Xiao; Le Xin; Zhuo Liu; Xiaolin Ma; Juan Sun; Qi Jin; Zhewei Liu
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

6.  Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo.

Authors:  Christopher C Kemball; Claudia T Flynn; Martin P Hosking; Jason Botten; J Lindsay Whitton
Journal:  Virology       Date:  2012-05-01       Impact factor: 3.616

7.  Deletions within the 5'UTR of coxsackievirus B3: consequences for virus translation and replication.

Authors:  Isabelle P Hunziker; Christopher T Cornell; J Lindsay Whitton
Journal:  Virology       Date:  2006-11-03       Impact factor: 3.616

8.  Viral proteinase requirements for the nucleocytoplasmic relocalization of cellular splicing factor SRp20 during picornavirus infections.

Authors:  Kerry D Fitzgerald; Amanda J Chase; Andrea L Cathcart; Genevieve P Tran; Bert L Semler
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Authors:  Nadine Althof; Stephanie Harkins; Christopher C Kemball; Claudia T Flynn; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

10.  The +4G site in Kozak consensus is not related to the efficiency of translation initiation.

Authors:  Xuhua Xia
Journal:  PLoS One       Date:  2007-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.